CAS: 1154757-24-0; Plazomicin
该化合物是一种合成的微粒球菌抗生素,主要用于治疗多抗药性抗淋病细菌引起的感染,其特点是其独特的结构,包括经改良的微粒球菌脊柱,增强其稳定性,以防治某些细菌酶,这些酶通常会抗其他异蚊菌素.甲虫菌菌表现出广泛的活动,特别是针对内科菌的,包括耐传统微粒菌的菌株.其行动机制与细菌性脊髓灰质炎有关,抑制蛋白综合,并最终导致细胞死亡.该物质通过静脉注射进行施用,主要指为复杂的尿道感染.甲虫菌的药性皮肤病表明人体组织中存在有利的分布,主要在尿液中出现异变.与其他微粒蛋白剂一样,在治疗期间,监测潜在的肾脏毒性和尿毒性至关重要.
- 英文名称Plazomicin
- 中文名称(S)-4-氨基-N-((1R,2S,3S,4R,5S)-5-氨基-4-(((2R,3R)-3-氨基-6-(((2-羟乙基)氨基)甲基)-3,4-二氢-2H-吡喃-2-基)氧基)-2-(((2R,3R,4R,5R)-3,5-二羟基-5-甲基-4-(甲基氨基)四氢-2H-吡喃-2-基)氧基)-3-羟基环己基)-2-羟基丁酰胺
- IUPAC名称(S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-4-(((2R,3R)-3-amino-6-(((2-hydroxyethyl)amino)methyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide
- CAS编号1154757-24-0
- MFCD编号:MFCD30533406
- FDA UNII编号:LYO9XZ250J
- 分子式:C25H48N6O10分子量:592.68282
- 产品CID: 191904
- 同类组份化合物CAS1154757-24-0 (free)1380078-95-4 (sulfate)
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12122769-B2
优先权日:2017-10-19
标题 :Synthesis of antibacterial aminoglycoside analogs
发明人：TREND RAISSA; DAPPEN MICHAEL; HENRY CHRISTOPHER E; GOLDBLUM ADAM AARON; AGGEN JAMES BRADLEY; MENDONÇA RICARDO FILIPE DE JESUS GONÇALVES; SARDINHA JOÃO CARLOS FALCÃO
权利人:CIPLA USA INC
摘要:The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.
专利号:EP-3697797-A1
优先权日:2017-10-19
标题 :Synthesis of antibacterial aminoglycoside analogs
专利号:CN-111655709-A
优先权日:2017-10-19
标 题:Synthesis of Antibacterial Aminoglycoside Analogs
专利号:JP-2023054316-A
优先权日:2017-10-19
标题 :Synthesis of antibacterial aminoglycoside analogues
专利号:WO-2019079613-A1
优先权日:2017-10-19
标题:SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGUES
专利号:US-11453658-B2
优先权日:2017-10-19
标 题 :Synthesis of antibacterial aminoglycoside analogs
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548540/ doi: 10.1007/s40121-019-0239-0. Epub 2019 Mar 9. Review.
3: Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. Drugs. 2019 Feb;79(3):243-269. doi: 10.1007/s40265-019-1054-3. Review. doi: 10.1002/phar.2203. Epub 2019 Jan 8. Review. doi: 10.1358/dot.2018.54.9.2874063. Review. Available from http://www.ncbi.nlm.nih.gov/books/NBK513053/ doi: 10.1517/13543784.2015.1095180. Epub 2015 Sep 30. Review. doi: 10.1586/eri.12.25. Review.
合成参考文献
参考文献:10.1128/aac.00099-14
摘要:Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother. 2014 Aug;58(8):4443–51.
参考文献:10.1007/s00108-015-3705-0
摘要:Kern WV. [New antibacterial agents on the market and in the pipeline]. Internist (Berl). 2015 Nov;56(11):1255–63. doi: 10.1007/s00108-015-3705-0.
参考文献:10.1007/s10928-017-9506-4
摘要:Bush K, Page MGP. What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. Journal of Pharmacokinetics and Pharmacodynamics. 2017 Feb 04;44(2):113–32. doi: 10.1007/s10928-017-9506-4.
参考文献:10.1007/s11908-018-0617-x
摘要:Porreca AM, Sullivan KV, Gallagher JC. The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms. Curr Infect Dis Rep. 2018 May 05;20(6):13. doi: 10.1007/s11908-018-0617-x.
📝 需求与反馈
尽可能描述清楚需求与问题信息
